Reed's (OTC:REED) Stock, Quote.Headers.trade-ideas

Reed's

Reed's Inc sells Ginger Beer brand. The company's portfolio of handcrafted, all natural beverages is sold in over 45,000 outlets nationwide including the natural and specialty food channel, grocery stores, mass merchants, drug stores, convenience stores, club stores, and on-premise locations including bars and restaurants. The company's two core brands are Reed's, which includes Reed's Craft Ginger Beer, Reed's Real Ginger Ale, Reed's Mules, and Reed's Hard Ginger Ale; and Virgil's Handcrafted sodas.

Reeds, Inc. Common Stock

Reeds

News

Penny Stocks

Small Cap

Markets

Trading Ideas

REED

WEST

Westrock Coffee Company (NASDAQ: WEST) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.

Westrock Coffee Company Reports Q1 Loss, Misses Revenue Estimates

Long Ideas

Insider Trades

Pre-Market Outlook

BBGI

COMM

SCKT

The Dow Jones closed slightly higher on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Insiders Buying CommScope Holding And 3 Other Stocks Under $3

Earnings

Guidance

General

Reed’s Inc (OTC: REED) reported a first-quarter FY23 sales decrease of 8.4% year-on-year to $11.16 million, missing the analyst consensus estimate of $14.12 million.

Reed&#39;s Earnings Miss Due To Tight Credit Terms, Expects To Turn Cash Flow Positive

Reed's Inc

REEDY LAGOON CORP LTD by REEDY LAGOON CORP LTD RICHMOND VIC

Reedy Lagoon Corp Ltd

Reed's Reiterates FY24 Financial Outlook For Net Sales Growth, Gross Margin Expansion & Achieve Modified EBITDA Profitability; Expects To Generate Positive Operating Cash Flow For FY24

Reed's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REED#NASDAQ">REED</a>) reported quarterly losses of $(0.77) per share which missed the analyst consensus estimate of $(0.15) by 413.33 percent. This is a 22.22 percent increase over losses of $(0.99) per share from the same period last year. The company reported quarterly sales of $11.87 million which beat the analyst consensus estimate of $11.47 million by 3.52 percent. This is a 18.68 percent increase over sales of $10.01 million the same period last year.

Reed's Q2 EPS $(0.77) Misses $(0.15) Estimate, Sales $11.87M Beat $11.47M Estimate

Reed's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REED#NASDAQ">REED</a>) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.46) by 13.04 percent. This is a 76.47 percent increase over losses of $(1.70) per share from the same period last year. The company reported quarterly sales of $9.60 million which missed the analyst consensus estimate of $13.37 million by 28.23 percent. This is a 14.00 percent decrease over sales of $11.16 million the same period last year.

Earnings Beats

Earnings Misses

Reed's Q1 EPS $(0.40) Beats $(0.46) Estimate, Sales $9.60M Miss $13.37M Estimate

Westrock Coffee Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/west#NASDAQ">WEST</a>) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -550%. A quarter ago, it was expected that this company would post earnings of $0.01 per share when it actually produced a loss of $0.05, delivering a surprise of -600%.
Over the last four quarters, the company has not been able to surpass consensus EPS estimates.
Westrock Coffee Company, which belongs to the Zacks Beverages - Soft drinks industry, posted revenues of $192.5 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 4.04%. This compares to year-ago revenues of $205.44 million. The company has not been able to beat consensus revenue estimates over the last four quarters.
The sustainability of the stock&#39;s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management&#39;s commentary on the earnings call.
Westrock Coffee Company shares have added about 3.7% since the beginning of the year versus the S&amp;P 500&#39;s gain of 8.8%.
What&#39;s Next for Westrock Coffee Company?
While Westrock Coffee Company has underperformed the market so far this year, the question that comes to investors&#39; minds is: what&#39;s next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company&#39;s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Westrock Coffee Company: unfavorable. While the magnitude and direction of estimate revisions could change following the company&#39;s just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.02 on $233.2 million in revenues for the coming quarter and -$0.04 on $946.8 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Beverages - Soft drinks is currently in the top 20% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Reeds (OTC: <a class="ticker" href="https://www.benzinga.com/stock/reed#OTC">REED</a>), has yet to report results for the quarter ended March 2024. The results are expected to be released on May 14.
This beverage and candy company is expected to post quarterly loss of $0.39 per share in its upcoming report, which represents a year-over-year change of +77.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Reeds&#39; revenues are expected to be $11.19 million, up 0.3% from the year-ago quarter.
<a href="https://www.zacks.com/stock/news/2271850/westrock-coffee-company-west-reports-q1-loss-misses-revenue-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-2271850">To read this article on Zacks.com click here.</a>

Reed's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REED#NASDAQ">REED</a>) reported quarterly losses of $(2.07) per share. The company reported quarterly sales of $11.700 million which missed the analyst consensus estimate of $14.084 million by 16.93 percent. This is a 22.21 percent decrease over sales of $15.040 million the same period last year.

Reed's Q4 2023 GAAP EPS $(2.07), Sales $11.700M Miss $14.084M Estimate

The Dow Jones closed slightly higher on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>CommScope Holding </h3>
<ul>
<li>The Trade: CommScope Holding Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/comm#NASDAQ">COMM</a>) SVP, Chief Legal Officer &amp; Sec Justin Choi <a href="https://www.benzinga.com/quote/COMM/analyst-ratings"> acquired a total of 28,600 shares </a> an average price of $1.74. To acquire these shares, it cost around $49,750.</li>
<li>What&rsquo;s Happening: On Nov. 9, CommScope reported third-quarter net sales of $1.6 billion.</li>
<li>What CommScope Holding Does: CommScope Holding Co Inc is a provider of infrastructure solutions for communication, data center and entertainment networks.</li>
</ul>
<h3>Reed&#39;s</h3>
<ul>
<li>The Trade: Reed&#39;s, Inc. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/reed#OTC">REED</a>) Director John Bello <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 5,000 shares </a> at an average price of $2.04. To acquire these shares, it cost around $10,200.</li>
<li>What&rsquo;s Happening: On Nov. 9, Reed&#39;s posted a narrower-than-expected quarterly loss.</li>
<li>What Reed&#39;s Does: Reed&#39;s Inc sells Ginger Beer brand. The company&#39;s portfolio of handcrafted, all-natural beverages is sold in over 45,000 outlets nationwide including the natural and specialty food channel, grocery stores, mass merchants, drug stores, convenience stores, club stores, and on-premise locations including bars and restaurants.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/23/11/36016489/investor-optimism-edges-lower-following-gdp-data"> Investor Optimism Edges Lower Following GDP Data </a>
<h3>Socket Mobile </h3>
<ul>
<li>The Trade: Socket Mobile, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sckt#NASDAQ">SCKT</a>) Director Charlie Bass <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 5,000 shares </a> at an average price of $1.40. The insider spent around $6,999 to buy those shares.</li>
<li>What&rsquo;s Happening: On Oct. 27, Socket Mobile posted a wider-than-expected third-quarter loss.</li>
<li>What Socket Mobile Does: Socket Mobile Inc is a producer of data capture products.</li>
</ul>
<h3>Beasley Broadcast Group </h3>
<ul>
<li>The Trade: Beasley Broadcast Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bbgi#NASDAQ">BBGI</a>) CEO Caroline Beasley <a href="https://www.benzinga.com/quote/RGF/analyst-ratings"> acquired a total of 2,825 shares </a> at an average price of $0.71. The insider spent around $2,005 to buy those shares.</li>
<li>What&rsquo;s Happening: On Nov. 1, Beasley Broadcast Group posted downbeat quarterly results.</li>
<li>What Beasley Broadcast Group Does: Beasley Broadcast Group Inc is a multi-platform media company, whose primary business is operating radio stations throughout the United States.</li>
</ul>
&nbsp;
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Reed's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REED#NASDAQ">REED</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.40) by 92.5 percent. This is a 98 percent increase over losses of $(1.50) per share from the same period last year. The company reported quarterly sales of $11.86 million which missed the analyst consensus estimate of $15.38 million by 22.91 percent. This is a 1.97 percent decrease over sales of $12.09 million the same period last year.

Reed's Q3 EPS $(0.03) Beats $(0.40) Estimate, Sales $11.86M Miss $15.38M Estimate

Reed's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REED#NASDAQ">REED</a>) is set to give its latest quarterly earnings report on Friday, 2023-11-10. Here's what investors need to know before the announcement.
Analysts estimate that Reed's will report an earnings per share (EPS) of $-0.40. 
Reed's bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.33, which was followed by a 8.3% increase in the share price the next day.
Here's a look at Reed's's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.32</td>
<td>-1.02</td>
<td>-1.28</td>
<td>-1.5</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.99</td>
<td>-1.70</td>
<td>-2.49</td>
<td>-1.5</td>
</tr>
<tr>
<td>Price Change %</td>
<td>8.3%</td>
<td>7.67%</td>
<td>-4.11%</td>
<td>-3.07%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2023/1699538455_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Reed's were trading at $2.95 as of November 07. Over the last 52-week period, shares are down 50.83%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/REED/earnings">To track all earnings releases for Reed's visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Reed's

Roth MKM analyst Sean McGowan maintains Reed's (OTC:<a class="ticker" href="https://www.benzinga.com/stock/REED#OTC">REED</a>) with a Buy and lowers the price target from $17 to $7.

Price Target

Analyst Ratings

Roth MKM Maintains Buy on Reed's, Lowers Price Target to $7

Reed's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REED#NASDAQ">REED</a>) reported quarterly losses of $(0.99) per share which beat the analyst consensus estimate of $(1.32) by 25 percent. This is a 60.4 percent increase over losses of $(2.50) per share from the same period last year. The company reported quarterly sales of $10.01 million which missed the analyst consensus estimate of $12.72 million by 21.34 percent. This is a 27.10 percent decrease over sales of $13.72 million the same period last year.

Reed's Q2 EPS $(0.99) Beats $(1.32) Estimate, Sales $10.01M Miss $12.72M Estimate

<a href="https://pro.benzinga.com/?utm_source=insights">According to data from Benzinga Pro,</a> during Q1, Reed's's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REED#NASDAQ">REED</a>) reported sales totaled $11.16 million. Despite a 35.63% increase in earnings, the company posted a loss of $4.36 million. Reed's collected $15.04 million in revenue during Q4, but reported earnings showed a $6.77 million loss. 
<h3>What Is Return On Capital Employed?</h3>
Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q1, Reed's posted an ROCE of 0.35%.
Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future. 
ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Reed's is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth. 
For Reed's, the positive return on capital employed ratio of 0.35% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.
<h3>Analyst Predictions</h3>
Reed's reported Q1 earnings per share at $-1.7/share, which did not meet analyst predictions of $-1.02/share.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Reed's's Return On Capital Employed Insights

Reed&rsquo;s Inc (OTC: <a class="ticker" href="https://www.benzinga.com/stock/reed#OTC">REED</a>) reported a <a href="https://www.benzinga.com/pressreleases/23/06/g32666215/reeds-reports-first-quarter-2023-results">first-quarter FY23 sales decrease of 8.4% </a>year-on-year to $11.16 million, missing the analyst consensus estimate of $14.12 million.
<ul>
<li>The decrease was primarily driven by tightened credit terms from several suppliers, impacting inventory.</li>
<li>EPS of $(1.70)<a href="https://www.benzinga.com/calendars/earnings"> missed</a> the analyst consensus of $(1.02).</li>
<li>The gross margin expanded by 10 basis points to 24.2%</li>
<li>Gross profit declined 6.8% to $2.7 million.</li>
<li>Selling, general and administrative expenses declined 27% to $3.2 million.</li>
<li>Operating loss improved to $(2.6) million compared to $(4.2) million last year.</li>
<li>The company held $467,000 in cash and equivalents as of March 31.</li>
<li>&quot;We continued to see solid order demand from our retail partners, however we were unable to fulfill orders due to tightened credit terms from several suppliers that impacted our ability to purchase inventory, which resulted in an inflated rate of short-order shipments, said CEO Norman E. Snyder.&nbsp;</li>
<li>Outlook: Reed sees <a href="https://www.benzinga.com/calendars/guidance">FY23 net sales</a> growth and gross margin to surpass 30%.</li>
<li>The company also expects to turn cash flow positive in the second half of 2023.</li>
</ul>
Price Action: REED shares closed higher by 11.15% at $3.39 on Wednesday.
&nbsp;

Reed's Earnings Miss Due To Tight Credit Terms, Expects To Turn Cash Flow Positive

Reeds currently expects FY23 gross margin to surpass 30%&nbsp;and modified EBITDA to turn profitable by 2H23. The company also expects to turn cash flow positive in 2H23.

Reeds Expects FY23 Gross Margin To Surpass 30% With Modified EBITDA Profitable By 2H23

Reed's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REED#NASDAQ">REED</a>) reported quarterly losses of $(1.70) per share which missed the analyst consensus estimate of $(1.02) by 66.67 percent. This is a 32 percent increase over losses of $(2.50) per share from the same period last year. The company reported quarterly sales of $11.16 million which missed the analyst consensus estimate of $14.12 million by 20.98 percent. This is a 8.41 percent decrease over sales of $12.18 million the same period last year.

Reed's Q1 EPS $(1.70) Misses $(1.02) Estimate, Sales $11.16M Miss $14.12M Estimate

Reed's (OTC:<a class="ticker" href="https://www.benzinga.com/stock/REED#OTC">REED</a>) reported its Q1 earnings results on Thursday, June 1, 2023 at 07:30 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Reed's missed estimated earnings by 66.67%, reporting an EPS of $-1.7 versus an estimate of $-1.02.
Revenue was down $1.02 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $1.21 which was followed by a 4.11% drop in the share price the next day.
Here's a look at Reed's's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
<th>Q2 2022</th>
<th>Q1 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.28</td>
<td>-1.5</td>
<td>-1</td>
<td>-2</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-2.49</td>
<td>-1.5</td>
<td>-2.5</td>
<td>-2.5</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>15.10M</td>
<td>16.91M</td>
<td>14.37M</td>
<td>13.10M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>15.04M</td>
<td>12.09M</td>
<td>13.72M</td>
<td>12.18M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Reed's <a href="https://www.benzinga.com/quote/REED/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Reed's: Q1 Earnings Insights

Reed's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REED#NASDAQ">REED</a>) is set to give its latest quarterly earnings report on Thursday, 2023-06-01. Here's what investors need to know before the announcement.
Analysts estimate that Reed's will report an earnings per share (EPS) of $-1.02. 
Reed's bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company missed EPS by $1.21, which was followed by a 4.11% drop in the share price the next day.
Here's a look at Reed's's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
<th>Q2 2022</th>
<th>Q1 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.28</td>
<td>-1.5</td>
<td>-1</td>
<td>-2</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-2.49</td>
<td>-1.5</td>
<td>-2.5</td>
<td>-2.5</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.11%</td>
<td>-3.07%</td>
<td>-7.55%</td>
<td>-2.27%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2023/1685548886_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Reed's were trading at $3.24 as of May 30. Over the last 52-week period, shares are down 69.47%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/REED/earnings">To track all earnings releases for Reed's visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Reed's

Reed's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REED#NASDAQ">REED</a>) reported quarterly losses of $(2.49) per share which missed the analyst consensus estimate of $(1.28) by 94.53 percent. This is a 0.4 percent increase over losses of $(2.50) per share from the same period last year. The company reported quarterly sales of $15.04 million which missed the analyst consensus estimate of $15.10 million by 0.40 percent. This is a 17.67 percent increase over sales of $12.78 million the same period last year.

Reed's Q4 EPS $(2.49) Misses $(1.28) Estimate, Sales $15.04M Miss $15.10M Estimate

Reed's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REED#NASDAQ">REED</a>) is set to give its latest quarterly earnings report on Wednesday, 2023-03-29. Here's what investors need to know before the announcement.
Analysts estimate that Reed's will report an earnings per share (EPS) of $-1.28. 
Reed's bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.00, which was followed by a 3.07% drop in the share price the next day.
Here's a look at Reed's's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2022</th>
<th>Q2 2022</th>
<th>Q1 2022</th>
<th>Q4 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.5</td>
<td>-1</td>
<td>-2</td>
<td>-2</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.5</td>
<td>-2.5</td>
<td>-2.5</td>
<td>-2.5</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.07%</td>
<td>-7.55%</td>
<td>-2.27%</td>
<td>-16.31%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2023/1680022868_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Reed's were trading at $3.41 as of March 27. Over the last 52-week period, shares are down 78.31%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/REED/earnings">To track all earnings releases for Reed's visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

<h3>Gainers</h3>
<ul>
<li>Sera Prognostics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sera#NASDAQ">SERA</a>) shares surged 63.4% to $2.11 after the company announced top-line data from the AVERT PRETERM TRIAL.</li>
<li>TransCode Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnaz#NASDAQ">RNAZ</a>) shares climbed 63.4% to $0.7684 after the company requested the withdrawal of a registration statement, saying it has determined not to pursue the sale of securities at this time.</li>
<li>Tenon Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tnon#NASDAQ">TNON</a>) rose 36.4% to $1.3513 after dropping 10% on Tuesday. Tenon Medical, during November, posted a Q3 loss of $0.28 per share.</li>
<li>Vallon Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vlon#NASDAQ">VLON</a>) shares rose 34.6% to $0.8771 after dropping 26% on Tuesday. Vallon Pharmaceuticals and GRI Bio recently announced they entered into a merger agreement.</li>
<li>Titan Medical Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdi#NASDAQ">TMDI</a>) jumped 33.8% to $0.18. The Nasdaq recently notified Titan Medical regarding Audit Committee requirements.</li>
<li>Roblox Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rblx#NYSE">RBLX</a>) shares climbed 24.8% to $44.54 after the company reported better-than-expected Q4 sales results.</li>
<li>NerdWallet, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrds#NASDAQ">NRDS</a>) surged 22% to $17.40 following strong quarterly results.</li>
<li>Cerberus Cyber Sentinel Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ciso#NASDAQ">CISO</a>) jumped 21% to $0.9300. Cerberus Sentinel recently announced a proposed public offering of common stock.</li>
<li>Upstart Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/upst#NASDAQ">UPST</a>) gained 20.6% to $20.34 after the company reported better-than-expected financial results but issued weak guidance.</li>
<li>The Trade Desk, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ttd#NASDAQ">TTD</a>) gained 19.4% to $59.76 after the company reported better-than-expected Q4 adjusted results and issued Q1 revenue guidance above estimates. The company also announced a $700 million buyback.</li>
<li>Atlis Motor Vehicles, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amv#NASDAQ">AMV</a>) jumped 20% to $1.86.</li>
<li>Sidus Space, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sidu#NASDAQ">SIDU</a>) gained 16% to $0.6778 after the company announced a $2.5 million agreement with the Netherlands for laser communication satellite.</li>
<li>Humanigen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hgen#NASDAQ">HGEN</a>) rose 15.3% to $0.2075. Humanigen received a notice of allowance for its U.S. patent application 16/652,977 titled &quot;Methods of Treating Immunotherapy-Related Toxicity Using a GM-CSF Antagonist.&quot;</li>
<li>Vapotherm, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vapo#NYSE">VAPO</a>) jumped 15% to $1.07. Vapotherm VP, Controller and CAO Dorota McKay acquired a total of 19,047 shares at an average price of $1.05.</li>
<li>Digital Ally, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dgly#NASDAQ">DGLY</a>) shares rose 13.3% to $4.59. Digital Ally sought withdrawal of the registration from the U.S. SEC. The company no longer wished to conduct a public offering of its securities.</li>
<li>Airbnb, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abnb#NASDAQ">ABNB</a>) rose 11.8% to $135.25 after the company reported strong earnings and sales results for its fourth quarter and issued strong Q1 sales forecast.</li>
<li>Herbalife Nutrition Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hlf#NYSE">HLF</a>) surged 11.8% to $19.43 following upbeat Q4 results.</li>
<li>OraSure Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/osur#NASDAQ">OSUR</a>) gained 10.5% to $5.41 after the company reported better-than-expected Q4 sales results. The company also issued Q1 2023 revenue guidance above estimates.</li>
<li>Healthcare Services Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hcsg#NASDAQ">HCSG</a>) rose 10.2% to $13.94 following upbeat Q4 results.</li>
<li>Pagaya Technologies Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pgy#NASDAQ">PGY</a>) jumped 9.6% to $1.4694 after the company reported better-than-expected Q4 adjusted EPS and sales results.</li>
<li>Nano Dimension Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nndm#NASDAQ">NNDM</a>) gained 9.3% to $2.8750. Nano Dimension initiated an active share repurchase process allowing the company to invest up to $100 million to repurchase its American Depository Shares.</li>
<li>BioSig Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bsgm#NASDAQ">BSGM</a>) rose 7.4% to $1.2910 after dropping 12% on Tuesday. BioSig Technologies reported the retirement of chief financial officer Steve Chaussy and named Steve Buhaly as his successor.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>GlycoMimetics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/glyc#NASDAQ">GLYC</a>) shares dipped 55.2% to $1.8150. GlycoMimetics reported continuation of Phase 3 study of e-selectin antagonist uproleselan in relapsed/refractory aml to originally planned final analysis following interim analysis by the independent Data Monitoring Committee.</li>
<li>Credo Technology Group Holding Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crdo#NASDAQ">CRDO</a>) shares dipped 47.2% to $10.22 after the company issued Q4 revenue guidance below analyst estimates.</li>
<li>T2 Biosystems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ttoo#NASDAQ">TTOO</a>) shares dropped 22% to $0.8405 after the company priced an 11.11 million share common stock offering at $1.08 per share.</li>
<li>Great Lakes Dredge &amp; Dock Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gldd#NASDAQ">GLDD</a>) fell 21% to $5.32 following Q4 results.</li>
<li>iPower Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ipw#NASDAQ">IPW</a>) fell 20.6% to $0.73 after the company reported worse-than-expected Q2 EPS and sales results.</li>
<li>Amesite Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amst#NASDAQ">AMST</a>) dropped 18.8% to $0.4137. Amesite recently announced GPT-3 powered functionality to its AI toolkit for customers and users.</li>
<li>Sabre Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sabr#NASDAQ">SABR</a>) dropped 18.7% to $5.60 after the company reported worse-than-expected Q4 adjusted EPS and sales results and issued guidance.</li>
<li>Amesite Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amst#NASDAQ">AMST</a>) fell 17.6% to $0.4201. Amesite shares jumped around 82% on Tuesday after the company announced GPT-3 powered functionality to its AI toolkit for customers and users.</li>
<li>Sunlands Technology Group (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/stg#NYSE">STG</a>) dropped 17.2% to $10.77.</li>
<li>Reed&#39;s, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/reed#NASDAQ">REED</a>) fell 17.2% to $2.84 after the company announced it will transition from the Nasdaq Capital Market to the OTCQX.</li>
<li>AMMO, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/poww#NASDAQ">POWW</a>) fell 16.9% to $1.87 after reporting downbeat Q3 sales.</li>
<li>Absolute Software Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abst#NASDAQ">ABST</a>) fell 16.2% to $9.55 following weak Q2 results.</li>
<li>Harpoon Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/harp#NASDAQ">HARP</a>) dropped 15.3% to $0.8301.</li>
<li>ContraFect Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cfrx#NASDAQ">CFRX</a>) fell 14.2% to $4.3250.</li>
<li>Entrada Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trda#NASDAQ">TRDA</a>) dropped 13.9% to $11.22.</li>
<li>Blue Water Vaccines, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bwv#NASDAQ">BWV</a>) shares fell 12.8% to $1.36. Blue Water Vaccines shares jumped 33% on Tuesday after a 13G filing showed Joseph Hernandez report an 18.43% passive stake in the company.</li>
<li>Devon Energy Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dvn#NYSE">DVN</a>) dropped 11.2% to $56.79 after the company posted downbeat Q4 results.</li>
<li>Hecla Mining Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hl#NYSE">HL</a>) fell 10.5% to $5.06 following Q4 results.</li>
<li>Akamai Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akam#NASDAQ">AKAM</a>) dropped 10% to $79.06 after the company reported Q4 financial</li>
<li>results. Following earnings, RBC Capital downgraded the stock from Outperform to Sector Perform and announced an $85 price target.</li>
<li>Hempacco Co., Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hpco#NASDAQ">HPCO</a>) fell 10% to $1.35. Hempacco reported closing of upsized $7.245 million public offering including full exercise of over-allotment option.</li>
<li>Barclays PLC (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bcs#NYSE">BCS</a>) tumbled 9.2% to $8.37 after the company reported a 14% decline in annual profits.</li>
<li>Ouster, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/oust#NYSE">OUST</a>) shares fell 9.1% to $1.50 after gaining 20% on Tuesday. Ouster is scheduled to report its financial results for the fourth quarter after the market closes on March 23, 2023.</li>
<li>Athenex, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atnx#NASDAQ">ATNX</a>) fell 9% to $3.1999.</li>
<li>ImmunityBio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ibrx#NASDAQ">IBRX</a>) dropped 8% to $3.44. ImmunityBio announced execution of $50 million equity financing with multiple institutional investors.</li>
<li>Taiwan Semiconductor Manufacturing Company Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tsm#NYSE">TSM</a>) shares dropped 6.2% to $91.85 after Berkshire Hathaway disclosed it cut its stake in the company by 86.2%.</li>
<li>Mullen Automotive, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/muln#NASDAQ">MULN</a>) shares declined 6.2% to $0.3530. Mullen Automotive filed for mixed-securities shelf offering.</li>
<li>Mercury General Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mcy#NYSE">MCY</a>) fell 5% to $35.33 following Q4 results.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/23/02/30925704/bitcoin-rises-above-this-key-level-immutablex-among-top-gainers"> Bitcoin Rises Above This Key Level; ImmutableX Among Top Gainers</a>

Intraday Update

Movers

ABNB

ABST

AKAM

AMST

Alternative Asset Management Acquisition Corp

ATNX

BSGM

CFRX

CISO

CRDO

DGLY

GLDD

GLYC

HARP

HCSG

HGEN

HPCO

IBRX

MULN

NNDM

NRDS

OSUR

OUST

POWW

RBLX

RNAZ

SABR

SERA

SIDU

TMDI

TNON

TRDA

TTOO

UPST

VAPO

VLON

Why Sabre Are Trading Lower By 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

WIIM

Reed's shares are trading lower after the company announced it will transition from the Nasdaq Capital Market to the OTCQX.

Reed's, Inc. (REED) Q1 2024 Earnings Call Transcript

The latest announcement is out from Reed's (REED). Reed's, Inc. successfully amended their financing strategy by entering into an Exercise and Amen...

Reed's Refinances, Offers New Notes, and Revamps Leadership

Reed's Q2 2024 Earnings Preview

Here's the major earnings after the close today

Reed's Non-GAAP EPS of -$0.16, revenue of $11.9M

Reed's (REED) has issued an update. The latest financial performance details provided in a recent report are for informational purposes only and ha...

Reed's Unofficial Financial Performance Disclosure

Reed's, Inc. (REED) Q2 2024 Earnings Call Transcript

Warning: REED is at high risk of performing badly

ACHV

ARMN

ASXC

BEEM

CTSO

CURI

DPRO

DRRX

FLUT

GROY

HIVE

IMOS

KNTNF

LAAC

LGMK

MRCY

NVVE

NWHUF

QFIN

QUIK

RKDA

SHWZ

VTGN

WPRT

ZVRA

Press Releases

Federman & Sherwood Announces Investigation Into Reeds, Inc.

Reed's Announces Limited Waiver and Amendment with its Secured Note Holder, Closing of a $3.8 Million SAFE and Planned Rights Offering to Stockholders

Reed's Schedules Fourth Quarter and Full Year 2023 Conference Call for March 28 at 5:00 p.m. ET

Reed's Reports Fourth Quarter and Full Year 2023 Results and Issues 2024 Financial Outlook

Reed's Schedules First Quarter 2024 Conference Call for May 14 at 5:00 p.m. ET

Reed's Reports First Quarter 2024 Results

Reed's Unveils New Virgil's 12oz Can Format in Sprouts Farmers Market

Reed's Schedules Second Quarter 2024 Conference Call for August 13 at 5:00 p.m. ET

Reed's Reports Second Quarter 2024 Results

Financing

Reed's Announces Closing of $6.0 Million Financing

Roth MKM

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Reed's

Reed's (REED) Forecast

Reed's (OTC:REED) Stock, Quote.Headers.trade-ideas